RT Journal Article
SR Electronic
T1 Overlap of high-risk individuals across family history, genetic & non-genetic breast cancer risk models: Analysis of 180,398 women from European & Asian ancestries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.27.25323002
DO 10.1101/2025.02.27.25323002
A1 Ho, Peh Joo
A1 Loo, Christine Kim Yan
A1 Goh, Meng Huang
A1 Abubakar, Mustapha
A1 Ahearn, Thomas U.
A1 Andrulis, Irene L.
A1 Antonenkova, Natalia N.
A1 Aronson, Kristan J.
A1 Augustinsson, Annelie
A1 Behrens, Sabine
A1 Bodelon, Clara
A1 Bogdanova, Natalia V.
A1 Bolla, Manjeet K.
A1 Brantley, Kristen
A1 Brenner, Hermann
A1 Byers, Helen
A1 Camp, Nicola J.
A1 Castelao, Jose E.
A1 Cessna, Melissa H.
A1 Chang-Claude, Jenny
A1 Chanock, Stephen J.
A1 Chenevix-Trench, Georgia
A1 Choi, Ji-Yeob
A1 Colonna, Sarah V.
A1 Czene, Kamila
A1 Daly, Mary B.
A1 Derouane, Francoise
A1 Dörk, Thilo
A1 Eliassen, A. Heather
A1 Engel, Christoph
A1 Eriksson, Mikael
A1 Evans, D. Gareth
A1 Fletcher, Olivia
A1 Fritschi, Lin
A1 Gago-Dominguez, Manuela
A1 Genkinger, Jeanine M.
A1 Geurts-Giele, Willemina R.R.
A1 Glendon, Gord
A1 Hall, Per
A1 Hamann, Ute
A1 Ho, Cecilia Y.S.
A1 Ho, Weang-Kee
A1 Hooning, Maartje J.
A1 Hoppe, Reiner
A1 Howell, Anthony
A1 Humphreys, Keith
A1 ABCTB Investigators
A1 kConFab Investigators
A1 SGBCC Investigators
A1 MyBrCa Investigators
A1 Ito, Hidemi
A1 Iwasaki, Motoki
A1 Jakubowska, Anna
A1 Jernström, Helena
A1 John, Esther M.
A1 Johnson, Nichola
A1 Kang, Daehee
A1 Kim, Sung-Won
A1 Kitahara, Cari M.
A1 Ko, Yon-Dschun
A1 Kraft, Peter
A1 Kwong, Ava
A1 Lambrechts, Diether
A1 Larsson, Susanna
A1 Li, Shuai
A1 Lindblom, Annika
A1 Linet, Martha
A1 Lissowska, Jolanta
A1 Lophatananon, Artitaya
A1 MacInnis, Robert J.
A1 Mannermaa, Arto
A1 Manoukian, Siranoush
A1 Margolin, Sara
A1 Matsuo, Keitaro
A1 Michailidou, Kyriaki
A1 Milne, Roger L.
A1 Taib, Nur Aishah Mohd
A1 Muir, Kenneth
A1 Murphy, Rachel A.
A1 Newman, William G.
A1 O’Brien, Katie M.
A1 Obi, Nadia
A1 Olopade, Olufunmilayo I.
A1 Panayiotidis, Mihalis I.
A1 Park, Sue K.
A1 Park-Simon, Tjoung-Won
A1 Patel, Alpa V.
A1 Peterlongo, Paolo
A1 Plaseska-Karanfilska, Dijana
A1 Pylkäs, Katri
A1 Rashid, Muhammad U.
A1 Rennert, Gad
A1 Rodriguez, Juan
A1 Saloustros, Emmanouil
A1 Sandler, Dale P.
A1 Sawyer, Elinor J.
A1 Scott, Christopher G.
A1 Shahi, Shamim
A1 Shu, Xiao-Ou
A1 Shulman, Katerina
A1 Simard, Jacques
A1 Southey, Melissa C.
A1 Stone, Jennifer
A1 Taylor, Jack A.
A1 Teo, Soo-Hwang
A1 Teras, Lauren R.
A1 Terry, Mary Beth
A1 Torres, Diana
A1 Vachon, Celine M.
A1 Van Houdt, Maxime
A1 Verhoeven, Jelle
A1 Weinberg, Clarice R.
A1 Wolk, Alicja
A1 Yamaji, Taiki
A1 Yip, Cheng Har
A1 Zheng, Wei
A1 Hartman, Mikael
A1 Li, Jingmei
YR 2025
UL http://medrxiv.org/content/early/2025/03/03/2025.02.27.25323002.abstract
AB Background Breast cancer is multifactorial. Focusing on limited risk factors may miss high-risk individuals.Methods We assessed the performance and overlap of various risk factors in identifying high-risk individuals for invasive breast cancer (BrCa) and ductal carcinoma in situ (DCIS) in 161,849 European-ancestry and 18,549 Asian-ancestry women. Discriminatory ability was evaluated using the area under the receiver operating characteristic curve (AUC). High-risk criteria included: 5-year absolute risk ≥1·66% by the Gail model [GAILbinary]; first-degree family history of breast cancer [FHbinary]; 5-year absolute risk ≥1·66% by a 313-variants polygenic risk score [PRSbinary]; and carriers of pathogenic variants in breast cancer predisposition genes [PTVbinary].Findings The 5-year absolute risk by PRS outperformed the Gail model in predicting BrCa (Europeansvs controls: AUCPRS=0·635 [0·632-0·638] vs AUCGail=0·492 [0·489-0·495]; Asiansvs controls: AUCPRS=0·564 [0·556-0·573] vs AUCGail=0·506 [0·497-0·514]). PRSbinary and GAILbinary identified more high-risk European than Asia individuals. High-risk proportions were higher among BrCa (16-26%) and DCIS (20-33%) compared to controls (9-15%) among young Europeans and all Asians. Fewer than 7% of BrCa, 10% of DCIS, and 3% of controls were classified as high-risk by multiple risk classifiers. Overlap between PRSbinary and PTVbinary was minimal (<0·65% Europeans, <0·15% Asians) compared to the proportion at high risk using PTVbinary alone (Europeans: 4·6%, Asians: 4·4%) and PRSbinary alone (Europeans: 13·9%, Asians: 8·5%). PRSbinary and FHbinary uniquely identified 5-6% and 9-11% of young BrCa, respectively.Interpretation The incomplete overlap between high-risk individuals identified by PRSbinary, GAILbinary, FHbinary, and PTVbinary highlights the need for a comprehensive approach to breast cancer risk prediction.SIGNIFICANCE This study shows that different ways of predicting breast cancer risk do not always flag the same people, suggesting that combining multiple risk factors could improve early detection and screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by the Agency for Science, Technology and Research (A*STAR) and PRECISION Health Research, Singapore (PRECISE). The breast cancer genome-wide association analyses in BCAC were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministere de l'Economie, de la Science et de l'Innovation du Quebec through Genome Quebec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710), and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Additional Materials (BCAC Funding and Acknowledgments). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the A*STAR Institutional Review Board (reference number: 2022-041).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes